Sequential treatment of recurrent mesenteric desmoid tumor

Cancer. 1996 Mar 15;77(6):1061-5.

Abstract

Background: The optimal management of inoperable desmoid tumors is still unclear. We report a 26 year-old female patient with familial adenomatous polyposis suffering from a recurrent inoperable intraabdominal desmoid tumor and its sequential treatment.

Methods: Treatment strategies included low-dose tamoxifen (30 mg orally per day), high-dose tamoxifen (90 mg orally per day), and a subsequent combination of goserelin acetate (3.6 mg subcutaneously once every four weeks) plus low-dose tamoxifen, medroxyprogesterone acetate (1000 mg orally per day) and interferon gamma (3 Mio IU subcutaneously 3 times a week).

Results: The combination of goserelin acetate and low-dose tamoxifen resulted in a decrease in tumour size and a complete relief of symptoms for 17 months. Thereafter the tumor progressed and again growth was stopped with interferon gamma therapy for another 6 months. All other treatment modalities had no effect.

Conclusions: This study demonstrates long-term regression of a desmoid tumor with combined endocrine therapy using goserelin acetate plus tamoxifen. Tumor progression after 17 months was again stopped by a combination of interferon-gamma and goserelin acetate.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adenomatous Polyposis Coli / pathology
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Drug Administration Schedule
  • Female
  • Fibromatosis, Aggressive / diagnostic imaging
  • Fibromatosis, Aggressive / therapy*
  • Goserelin / administration & dosage
  • Humans
  • Interferon-gamma / administration & dosage
  • Medroxyprogesterone / administration & dosage
  • Mesentery*
  • Neoplasm Recurrence, Local
  • Neoplasms, Multiple Primary
  • Peritoneal Neoplasms / diagnostic imaging
  • Peritoneal Neoplasms / therapy*
  • Tamoxifen / administration & dosage
  • Tomography, X-Ray Computed

Substances

  • Tamoxifen
  • Goserelin
  • Interferon-gamma
  • Medroxyprogesterone